Member Info for OAPK20

Seems E3 still sell into any volume

CDT up 😁

Behaving like a wildcat not confirming testing but keeping people guessing.

How long to move then set up the wireline logging unit ? All in place for Monday ?

Don’t know if you’ve seen this Joe.

https://uk.finance.yahoo.com/news/conduit-pharma-ceo-tapolczay-biopharma-132916007.html

Is the Jury out on finance.

Any thoughts?

No RNS. No confirmation. No market confidence. Tick tock

$0.67

Widglide "shafted by the BOB" - is that the same as being shafted by the BOBBY ?

Or did you mean BOD?

Joe sell up and enjoy your cash mate because if CDT goes to current cash position you are going to explode. Have you even read the documents?

"Following the completion of the Business Combination and the closing of the PIPE Financing, the most significant change in our future reported financial position and result of operations was an estimated increase in cash (as compared to our balance sheet as of June 30, 2023) to approximately $4.4 million after redemptions, including $20.0 million in gross proceeds from the PIPE Financing. Total direct transaction costs of MURF and Conduit are estimated at approximately $18.5 million, substantially all of which was recorded as a reduction to additional paid-in-capital as costs related to the reverse recapitalization. For additional information refer to the information attached as Exhibit 99.3 to this Current Report."

"Cash and Cash Equivalents

Cash and cash equivalents are primarily maintained with major financial institutions in the United Kingdom and Switzerland. The Company considers cash equivalents to be short-term, highly liquid investments that (a) are readily convertible into known amounts of cash, (b) are traded and held for cash management purposes, and (c) have original maturities of three months or less at the time of purchase. The Switzerland bank accounts holding cash balances are uninsured. The Company has not experienced any losses on this account through the period ended June 30, 2023.

The Company did not hold any cash equivalents as of June 30, 2023 and December 31, 2022."

Has the placing overhang cleared or is there still block selling expected above 12p.

No it was a source of funding which is now significantly devalued. If the CDT sp doesn’t recover to $10 CIZ are out of pocket.

They have the £500k drawdown facility which it looks increasingly more likely they’ll need. That leads to more dilution. If they cant achieve their aims within that current funding they will need more financing which again is likely to be dilutive to current holders.

The presentation at the US biomarker event is going to be interesting. It would be good to have a progress update beforehand but don’t hold your breath.

Been a poor listing for CDT. Think it’s heading to cash value if they don’t get a shift on with news

Fingers crossed but “never assume” etc

assuming that the wireline logging unit is released from its present contract on or before 10 October 2023. The Company will provide an update if there is any change to this date.

Anyone attending or have access to the Prof’s presentation?

Capital Expenditures

We currently anticipate that cash required for capital expenditures for the next 12 months is approximately $6.9 million, which includes accrued expenses of $3.7 million and a note payable of $0.2 million that matures within the next 12 months. We do not anticipate being able to fund required capital expenditures for the next 12 months with cash and cash equivalents on hand as we have a history of limited cash on hand. Management believes that we will be able to fund cash required for the next 12 months through the issuance of existing convertible loan note instruments and the issuance of new convertible loan note instruments. We have historically been able to access funds through the issuance of our convertible notes and believe we can continue to obtain funding through these debt financing agreements as needed to meet cash requirements for the next 12 months.

Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth in the section titled “Risk Factors—Risks Related to Conduit’s Business and Industry.”

Going to be a slog for the Conduit SP until news. CDT can issue up to 250M new shares. CIZ own progress is key within current available funding (w/o Put option proceeds)

We are led by highly experienced pharma executives, Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer Inc., and Dr. David Tapolczay, former Chief Executive Officer of the United Kingdom-based medical research charity LifeArc.

Our current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto’s Thyroiditis, preterm labor and renal transplant rejection. Our development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

We have an exclusive relationship and partnership with St George Street Capital (“SGSC”), a biomedical charity based in the United Kingdom. We fund the development of clinical assets that are initially licensed by SGSC from its existing relationship with AstraZeneca AB (PUBL). We conduct clinical trials on the clinical assets that we license from AstraZeneca in collaboration with SGSC. In doing so, we are able to leverage the comprehensive clinical and scientific expertise in order to develop assets through Phase IIb trials in an efficient manner. We expect that successful Phase IIb trials on the assets in our pipeline will increase the value of the assets.

Following successful clinical trials, we expect to commercialize the clinical assets in our pipeline through licensing arrangements with larger pharmaceuticals companies, which may include up-front milestone payments and/or royalties during the time at which such clinical asset is subject to patents.

We intend to use the income received from licensing our clinical assets to fund the development of additional clinical assets. This will allow us to use the existing income stream from clinical assets that have been licenses to fund our on-going operations without having to rely solely on debt and/or equity financing. We initially intend to focus on assets that have been deprioritized by larger pharmaceuticals companies and that have a high unmet medical need in order to develop these assets through the Phase IIb stage. We also believe that we may be able to apply our business strategy and approach to arrangements to pharmaceutical companies in addition to AstraZeneca.

We have incurred significant operating losses since inception. For the six months ended June 30, 2023 and 2022, our net loss was $4.7 million and $0.9 million, respectively, and we expect to continue to incur significant losses for the foreseeable future as we continue to invest in a number of research and development programs. As of June 30, 2023, we had an accumulated deficit of $15.4 million.

Presidio Property Trust, Inc., (NASDAQ: SQFT; SQFTP; SQFTW) (“Presidio” or the “Company”), today announced the successful merger with and commencement of trading of Conduit Pharmaceuticals, Inc., now trading on Nasdaq under the ticker symbol CDT for common stock on the Global Market and ticker symbol CDTTW for warrants on the Capital Market. In connection with the completion of the merger, Presidio’s sponsored SPAC Murphy Canyon Acquisition Corp. changed its name to Conduit Pharmaceuticals Inc. Conduit is a disease agnostic multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development. The transition highlights Presidio’s commitment to innovative growth strategies and broadening its investment portfolio.

The merger process was completed on September 22, 2023, following the definitive business combination agreement announced previously. As a result of this transaction, Presidio now owns a total of 4,015,250 shares of Conduit and warrants to purchase 709,000 shares of Conduit.

“Presidio is proud to have been a part of this successful SPAC transaction, reflecting our confidence in the growth and future prospects of Conduit,” said Jack Heilbron, CEO of Presidio Property Trust. “We firmly believe in the strategy and leadership of Conduit, and we are excited about the possibilities that this de-SPAC brings to Presidio’s shareholders, which can now finally be recognized as an asset on Presidio’s balance sheet.”

In a latest emailed statement, Aramco said it seeks to “become a leading global LNG player”, as it sees growing demand for the fuel.

“We see indications that the LNG market is positioned for structural, long-term growth,” Bloomberg quoted Aramco’s Upstream President Nasir Al-Naimi as saying. The official confirmed plans to diversify Aramco’s business and tap into demand for gas and cleaner energy options.

Global LNG trade doubled in value last year to more than $450 billion, according to the International Energy Agency. The growth in LNG demand has been attributed to supply disruptions caused by the Russia-Ukraine conflict.

The oil giant has allocated a huge spending outlay of $45 billion to $55 billion this year, as it looks to expand its investments.